Q: Why are there relatively few venture-financed spin-offs from pharmaceutical companies, despite the apparent attractiveness of this type of transaction to both venture funds and pharma companies?
The Trouble with Spin-Offs
Drug firms have created relatively few venture-financed spin-offs. The central reason--the valuation impasse between VC and pharma--is as much pscyhologically rooted as financially.